Influence of histocompatibility genes on the clinical course of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a

被引：0
|
作者：
Fletcher, S.
Klein, T.
Pollak, L.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S200 / S201
页数：2
相关论文
共 50 条
  • [21] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
  • [22] The use of interferon beta in relapsing-remitting multiple sclerosis
    Etheridge, LJ
    Beverley, DW
    Ferrie, C
    McManus, E
    ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (08) : 789 - 791
  • [23] Clinical significance of antibodies to interferon beta therapy in patients with relapsing-remitting multiple sclerosis
    Bendtzen, Klaus
    CYTOKINE, 2009, 48 (1-2) : 21 - 21
  • [24] Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
    Khatri, Bhupendra
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kappos, Ludwig
    Montalban, Xavier
    Pelletier, Jean
    Stites, Tracy
    Wu, Stacy
    Holdbrook, Fred
    Zhang-Auberson, Lixin
    Francis, Gordon
    Cohen, Jeffrey A.
    Cohen, J.
    Barkhof, F.
    Comi, G.
    Hartung, H.P.
    Khatri, B.
    Montalban, X.
    Pelletier, J.
    Easton, D.
    Calandra, T.
    DiMarco, J.
    Hudson, L.
    Kesselring, J.
    Laupacis, A.
    Temkin, N.
    Weinshenker, B.
    Zarbin, M.
    Barkhof, F.
    Poppe, P.
    Luetic, G.
    Cristiano, E.
    Caceres, F.
    Garcea, O.
    Correale, J.
    Ballario, C.
    Piedrabuena, R.
    Pollard, J.
    Beran, R.
    Hodgkinson, S.
    Schwartz, R.
    Heard, R.
    King, J.
    Butzkueven, H.
    Maida, E.M.
    Vass, K.
    Franta-Elmer, C.
    Berger, T.
    Aichner, F.
    LANCET NEUROLOGY, 2011, 10 (06): : 520 - 529
  • [25] Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study
    Etemadifar, Masoud
    Kazemi, Mojtaba
    Chitsaz, Ahmad
    Hekmatnia, Ali
    Tayari, Nazila
    Ghazavi, Amirhossein
    Maghzi, Amir Hadi
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2011, 16 (01): : 1 - 5
  • [26] Impact of discontinuing interferon beta in patients with relapsing-remitting multiple sclerosis
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [27] Quality of life in 1000 patients with relapsing-remitting multiple sclerosis and the impact of treatment initiation with intramuscular interferon beta-1a
    Putzki, Norman
    Hartung, Hans Peter
    MULTIPLE SCLEROSIS, 2008, 14 : S149 - S149
  • [28] Estimating Net Health Benefits of Intramuscular Interferon Beta-1a and Fingolimod in Treating Patients with Relapsing-Remitting Multiple Sclerosis
    Szabo, Shelagh
    Dembek, Carole
    Moore, Peter
    White, Leigh Ann
    Wijaya, Hardy
    Levy, Adrian
    NEUROLOGY, 2012, 78
  • [29] ESTIMATING NET HEALTH BENEFITS OF INTRAMUSCULAR INTERFERON BETA-1A AND FINGOLIMOD IN TREATING PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Szabo, S. M.
    Dembek, C.
    Moore, P.
    White, L. A.
    Wijaya, H.
    Levy, A. R.
    VALUE IN HEALTH, 2011, 14 (07) : A317 - A317
  • [30] Interferon beta-1a is efficacious and well tolerated by patients with relapsing-remitting multiple sclerosis who discontinue use of interferon beta-1b
    Wabant, EL
    Beccariam, L
    Andersson, PB
    ANNALS OF NEUROLOGY, 1997, 42 (03) : T293 - T293
12345